These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 9474188)

  • 41. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy.
    Wu TT; Wang JS; Lu CM; Lee YH; Huang JK
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy.
    Blute ML; Bergstralh EJ; Iocca A; Scherer B; Zincke H
    J Urol; 2001 Jan; 165(1):119-25. PubMed ID: 11125379
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
    Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
    Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1.
    Korkolopoulou P; Christodoulou P; Konstantinidou AE; Thomas-Tsagli E; Kapralos P; Davaris P
    Hum Pathol; 2000 Jun; 31(6):751-60. PubMed ID: 10872671
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kurahashi T; Miyake H; Hara I; Fujisawa M
    J Urol; 2007 Feb; 177(2):757-61. PubMed ID: 17222676
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Miyake H; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Urol Oncol; 2010; 28(2):145-51. PubMed ID: 18848789
    [TBL] [Abstract][Full Text] [Related]  

  • 49. p53 nuclear protein expression is an independent prognostic marker in clinically localized prostate cancer patients undergoing radical prostatectomy.
    Bauer JJ; Sesterhenn IA; Mostofi KF; McLeod DG; Srivastava S; Moul JW
    Clin Cancer Res; 1995 Nov; 1(11):1295-300. PubMed ID: 9815924
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
    Brewster SF; Oxley JD; Trivella M; Abbott CD; Gillatt DA
    J Urol; 1999 Apr; 161(4):1238-43. PubMed ID: 10081877
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy.
    Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Koutsilieris M
    Anticancer Res; 2005; 25(4):3123-33. PubMed ID: 16080576
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial V.
    Spataro VJ; Litman H; Viale G; Maffini F; Masullo M; Golouh R; Martinez-Tello FJ; Grigolato P; Shilkin KB; Gusterson BA; Castiglione-Gertsch M; Price K; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Collins J; Gelber RD; Coates AS; Goldhirsch A;
    Cancer; 2003 Apr; 97(7):1591-600. PubMed ID: 12655514
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
    Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
    J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Subclassification of clinical stage T1 prostate cancer: impact on biochemical recurrence following radical prostatectomy.
    Magheli A; Rais-Bahrami S; Carter HB; Peck HJ; Epstein JI; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1277-80; discussion 1280-1. PubMed ID: 17698121
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic markers in clinically localized prostate cancer.
    Pettaway CA
    Tech Urol; 1998 Mar; 4(1):35-42. PubMed ID: 9568775
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of p27(Kip1) expression in colorectal cancer: a clinico-pathological characterization.
    Palmqvist R; Stenling R; Oberg A; Landberg G
    J Pathol; 1999 May; 188(1):18-23. PubMed ID: 10398135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy.
    Kordan Y; Chang SS; Salem S; Cookson MS; Clark PE; Davis R; Herrell SD; Baumgartner R; Phillips S; Smith JA; Barocas DA
    J Urol; 2009 Nov; 182(5):2291-5. PubMed ID: 19758638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.